A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Conditions

• Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
• Squamous Lung Cancer With FGFR1 Amplification
• Bladder Cancer With FGFR3 Mutation or Fusion
• Advanced Solid Tumors With FGFR1 Amplication
• Advanced Solid Tumors With FGFR2 Amplication
• Advanced Solid Tumors With FGFR3 Mutation

Interventions

• DRUG: BGJ398

Sponsor

Novartis Pharmaceuticals